Targeted therapies: Afatinib--new therapy option for EGFR-mutant lung cancer

Nat Rev Clin Oncol. 2013 Oct;10(10):551-2. doi: 10.1038/nrclinonc.2013.154. Epub 2013 Aug 20.

Abstract

On 15 July 2013, the FDA approved afatinib as a first-line treatment for patients with metastatic non-small-cell lung cancer whose tumours harbour exon 19 deletions or exon 21 (L858R) EGFR substitution mutations. We discuss three recent studies investigating afatinib in this molecular subset of patients.

Publication types

  • News

MeSH terms

  • Afatinib
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / genetics
  • ErbB Receptors / antagonists & inhibitors*
  • ErbB Receptors / genetics
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Molecular Targeted Therapy*
  • Mutation / genetics*
  • Quinazolines / therapeutic use*

Substances

  • Quinazolines
  • Afatinib
  • EGFR protein, human
  • ErbB Receptors